Reneo Pharmaceuticals Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 8

Employees

  • Latest Deal Type
  • M&A

Reneo Pharmaceuticals General Information

Description

Reneo Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.

Contact Information

Website
www.reneopharma.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 18575 Jamboree Road
  • Suite 275-S
  • Irvine, CA 92612
  • United States
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Acquirer
OnKure Therapeutics
Vertical(s)
Life Sciences
Corporate Office
  • 18575 Jamboree Road
  • Suite 275-S
  • Irvine, CA 92612
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Reneo Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 04-Oct-2024 Completed Generating Revenue
6. Merger/Acquisition 25-Dec-2023 Cancelled Generating Revenue
5. PIPE 08-May-2023 Completed Generating Revenue
4. 2PO 04-May-2023 Completed Generating Revenue
3. IPO 09-Apr-2021 Completed Generating Revenue
2. Later Stage VC (Series B) 16-Mar-2021 $94.8M $145M Completed Clinical Trials - Phase 2
1. Later Stage VC (Series A) 09-May-2019 $50M $50M Completed Clinical Trials - Phase 1
To view Reneo Pharmaceuticals’s complete valuation and funding history, request access »

Reneo Pharmaceuticals Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B
Series A
To view Reneo Pharmaceuticals’s complete cap table history, request access »

Reneo Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Reneo Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the development of therapies for
Drug Discovery
Irvine, CA
8 As of 2024

Plymouth Meeting, PA
 

Kalamazoo, MI
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Reneo Pharmaceuticals Competitors (57)

One of Reneo Pharmaceuticals’s 57 competitors is Harmony Biosciences Holdings, a Formerly VC-backed company based in Plymouth Meeting, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Harmony Biosciences Holdings Formerly VC-backed Plymouth Meeting, PA
Metabolic Solutions Development Company Venture Capital-Backed Kalamazoo, MI
Mission Therapeutics Venture Capital-Backed Cambridge, United Kingdom
Ayala Pharmaceuticals Corporation Wilmington, DE
Epirium Bio Venture Capital-Backed San Diego, CA
You’re viewing 5 of 57 competitors. Get the full list »

Reneo Pharmaceuticals Patents

  • 5

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • Pending

  • Expiring in next 12 mo

Reneo Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-11267795-B2 Crystalline ppar-delta agonist Inactive 22-Jul-2020
US-20220024888-A1 Crystalline ppar-delta agonist Active 22-Jul-2020
US-20220135532-A1 Crystalline ppar-delta agonist Active 22-Jul-2020
US-20240002356-A1 Crystalline ppar-delta agonist Inactive 22-Jul-2020
US-11713301-B2 Crystalline pparδ agonist Active 22-Jul-2020 C07D295/096
To view Reneo Pharmaceuticals’s complete patent history, request access »

Reneo Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Reneo Pharmaceuticals Former Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Abingworth Venture Capital Minority
Aisling Capital Venture Capital Minority
Amzak Capital Management Family Office Minority
Amzak Health Venture Capital Minority
Chiesi Ventures Corporate Venture Capital Minority
You’re viewing 5 of 13 investors. Get the full list »

Reneo Pharmaceuticals Investments & Acquisitions (2)

Reneo Pharmaceuticals’s most recent deal was a Reverse Merger with OnKure Therapeutics. The deal was made on 04-Oct-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
OnKure Therapeutics 04-Oct-2024 Reverse Merger Biotechnology
vTv Therapeutics (PPAR-delta program) 21-Dec-2017 Corporate Asset Purchase Buildings and Property
To view Reneo Pharmaceuticals’s complete investments and acquisitions history, request access »

Ready to get started?

Request a free trial

Reneo Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated February, 29, 2024

35.66 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,111

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 425

Rank

Percentile

To view Reneo Pharmaceuticals’s complete esg history, request access »

Reneo Pharmaceuticals FAQs

  • When was Reneo Pharmaceuticals founded?

    Reneo Pharmaceuticals was founded in 2014.

  • Where is Reneo Pharmaceuticals headquartered?

    Reneo Pharmaceuticals is headquartered in Irvine, CA.

  • What is the size of Reneo Pharmaceuticals?

    Reneo Pharmaceuticals has 8 total employees.

  • What industry is Reneo Pharmaceuticals in?

    Reneo Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Reneo Pharmaceuticals a private or public company?

    Reneo Pharmaceuticals is a Private company.

  • What is Reneo Pharmaceuticals’s current revenue?

    The current revenue for Reneo Pharmaceuticals is .

  • How much funding has Reneo Pharmaceuticals raised over time?

    Reneo Pharmaceuticals has raised $299M.

  • Who are Reneo Pharmaceuticals’s investors?

    Abingworth, Aisling Capital, Amzak Capital Management, Amzak Health, and Chiesi Ventures are 5 of 13 investors who have invested in Reneo Pharmaceuticals.

  • Who are Reneo Pharmaceuticals’s competitors?

    Harmony Biosciences Holdings, Metabolic Solutions Development Company, Mission Therapeutics, Ayala Pharmaceuticals, and Epirium Bio are some of the 57 competitors of Reneo Pharmaceuticals.

  • When was Reneo Pharmaceuticals acquired?

    Reneo Pharmaceuticals was acquired on 04-Oct-2024.

  • Who acquired Reneo Pharmaceuticals?

    Reneo Pharmaceuticals was acquired by OnKure Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process